ArticleHereditas2025
The diagnostic and predictive value of LncRNA PANDAR in gastric cancer and its regulation of gastric cancer progression via miR-637.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) remains a global health challenge due to its high morbidity, late-stage diagnosis, and limited therapeutic options. long non-coding RNA PANDAR has been implicated in tumorigenesis across multiple cancers, yet its role in GC pathogenesis and diagnostic utility is still unclear. The purpose of this study is to elucidate the diagnostic value of serum PANDAR and its regulatory mechanisms in GC progression.
methodslncRNA PANDAR levels were quantified in serum from 112 GC patients and 98 benign controls using RT-qPCR. The diagnostic value of lncRNA PANDAR was analyzed by ROC curve. Functional experiments (CCK-8, Transwell assays) and dual-luciferase reporter assays were conducted in HGC-27 and BGC-823 cells to explore the function of PANDAR in cell proliferation, migration, and invasion. The interaction between PANDAR and miR-637 was validated via bioinformatics prediction and co-inhibition assay.
resultsSerum PANDAR was significantly upregulated in GC patients (P < 0.0001) and exhibited high diagnostic accuracy (AUC = 0.913). Elevated PANDAR associated with advanced TNM stage (P = 0.047), lymph node metastasis (P = 0.023), and digestive system history (P = 0.035). PANDAR knockdown suppressed GC cell proliferation, migration, and invasion, effects reversed by co-inhibition of miR-637.
conclusionslncRNA PANDAR is a promising non-invasive diagnostic indicator of GC, and may serve as a biomarker for GC diagnosis and therapy. lncRNA PANDAR regulates the progression of GC through sponge miR-637.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.